Literature DB >> 26069021

Establishment of Patient-Derived Xenograft (PDX) Models of Human Breast Cancer.

Xiaomei Zhang1, Michael T Lewis1,2.   

Abstract

Patient-derived xenograft (PDX) models of human breast cancer are proving useful for preclinical evaluation of experimental therapeutics. However, until recently, generation of PDX models reflecting the full spectrum of human breast cancers has been an elusive goal. We recently developed a method for establishing serially transplantable, phenotypically stable, human breast cancer xenograft models in immunocompromised mice with comparatively high efficiency (overall ∼25%). These xenografts represent the major clinically defined subtypes of breast cancer [e.g. estrogen receptor positive (ER+), HER2 positive (HER2+), and "triple negative" (TN) breast cancers]. This method, and methods being developed in other laboratories, may soon allow for conducting "animal clinical trials" once sufficient numbers of clinically relevant models are generated. Curr. Protoc. Mouse Biol. 3:21-29 © 2013 by John Wiley & Sons, Inc.
Copyright © 2013 John Wiley & Sons, Inc.

Entities:  

Keywords:  NOD-SCID IL2Rgammanull immunocompromised mice (NSG); SCID/Beige immunocompromised mice; mammary gland; preclinical breast cancer models; transplantation methods

Year:  2013        PMID: 26069021     DOI: 10.1002/9780470942390.mo120140

Source DB:  PubMed          Journal:  Curr Protoc Mouse Biol        ISSN: 2161-2617


  21 in total

Review 1.  How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective.

Authors:  Matthew R Swiatnicki; Eran R Andrechek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-06-21       Impact factor: 2.673

2.  Detection and Elimination of Corynebacterium bovis from Barrier Rooms by Using an Environmental Sampling Surveillance Program.

Authors:  Christopher A Manuel; Umarani Pugazhenthi; Shannon P Spiegel; Jori K Leszczynski
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-03-01       Impact factor: 1.232

3.  Procedure for Horizontal Transfer of Patient-Derived Xenograft Tumors to Eliminate Corynebacterium bovis.

Authors:  Christopher A Manuel; Stacey M Bagby; Julie A Reisinger; Umarani Pugazhenthi; Todd M Pitts; Stephen B Keysar; John J Arcaroli; Jori K Leszczynski
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-03-01       Impact factor: 1.232

4.  TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.

Authors:  Tiara T Byrd; Kristen Fousek; Antonella Pignata; Christopher Szot; Heba Samaha; Steven Seaman; Lacey Dobrolecki; Vita S Salsman; Htoo Zarni Oo; Kevin Bielamowicz; Daniel Landi; Nino Rainusso; John Hicks; Suzanne Powell; Matthew L Baker; Winfried S Wels; Joachim Koch; Poul H Sorensen; Benjamin Deneen; Matthew J Ellis; Michael T Lewis; Meenakshi Hegde; Bradley S Fletcher; Brad St Croix; Nabil Ahmed
Journal:  Cancer Res       Date:  2017-11-28       Impact factor: 12.701

5.  Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer.

Authors:  James D Hampton; Erica J Peterson; Nicholas P Farrell; Jennifer E Koblinski; Samantha J Katner; Tia H Turner; Mohammad A Alzubi; J Chuck Harrell; Mikhail G Dozmorov; Joseph B McGee Turner; Pam J Gigliotti; Vita Kraskauskiene; Mayuri Shende; Michael O Idowu; Madhavi Puchalapalli; Bin Hu; Larisa Litovchick; Eriko Katsuta; Kazuaki Takabe
Journal:  Mol Cancer Ther       Date:  2021-11-23       Impact factor: 6.009

6.  A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.

Authors:  Xiaomei Zhang; Sofie Claerhout; Aleix Prat; Lacey E Dobrolecki; Ivana Petrovic; Qing Lai; Melissa D Landis; Lisa Wiechmann; Rachel Schiff; Mario Giuliano; Helen Wong; Suzanne W Fuqua; Alejandro Contreras; Carolina Gutierrez; Jian Huang; Sufeng Mao; Anne C Pavlick; Amber M Froehlich; Meng-Fen Wu; Anna Tsimelzon; Susan G Hilsenbeck; Edward S Chen; Pavel Zuloaga; Chad A Shaw; Mothaffar F Rimawi; Charles M Perou; Gordon B Mills; Jenny C Chang; Michael T Lewis
Journal:  Cancer Res       Date:  2013-06-04       Impact factor: 12.701

7.  mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.

Authors:  Wei Mo; Qingxin Liu; Curtis Chun-Jen Lin; Hui Dai; Yang Peng; Yulong Liang; Guang Peng; Funda Meric-Bernstam; Gordon B Mills; Kaiyi Li; Shiaw-Yih Lin
Journal:  Clin Cancer Res       Date:  2015-11-06       Impact factor: 12.531

8.  DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-Positive Breast Cancer Following Endocrine Therapy.

Authors:  Daniel S Peiffer; Debra Wyatt; Andrei Zlobin; Ali Piracha; Jeffrey Ng; Andrew K Dingwall; Kathy S Albain; Clodia Osipo
Journal:  Cancer Res       Date:  2019-08-06       Impact factor: 12.701

Review 9.  Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Authors:  Lacey E Dobrolecki; Susie D Airhart; Denis G Alferez; Samuel Aparicio; Fariba Behbod; Mohamed Bentires-Alj; Cathrin Brisken; Carol J Bult; Shirong Cai; Robert B Clarke; Heidi Dowst; Matthew J Ellis; Eva Gonzalez-Suarez; Richard D Iggo; Peter Kabos; Shunqiang Li; Geoffrey J Lindeman; Elisabetta Marangoni; Aaron McCoy; Funda Meric-Bernstam; Helen Piwnica-Worms; Marie-France Poupon; Jorge Reis-Filho; Carol A Sartorius; Valentina Scabia; George Sflomos; Yizheng Tu; François Vaillant; Jane E Visvader; Alana Welm; Max S Wicha; Michael T Lewis
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

Review 10.  Engineering complexity in human tissue models of cancer.

Authors:  Kacey Ronaldson-Bouchard; Ilaria Baldassarri; Daniel Naveed Tavakol; Pamela L Graney; Maria Samaritano; Elisa Cimetta; Gordana Vunjak-Novakovic
Journal:  Adv Drug Deliv Rev       Date:  2022-03-09       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.